News

News 20.12.2023 SCHLIEREN, Switzerland & ROCKVILLE, Md.--(BUSINESS WIRE)--LimmaTech Biologics and AbVacc announced today a license agreement that grants LimmaTech the exclusive rights to further develop AbVacc’s multivalent toxoid vaccine candidate, LBT-SA7 (formerly IBT-V02), designed to prevent infections caused by the bacterial pathogen, Staphylococcus aureus (S. aureus). LimmaTech also receives an exclusive option, executable post Phase 1...

News 20.12.2023 Topadur Pharma AG and Juvic Inc. Launch Transnational Collaboration for the Disease Management of Systemic Sclerosis Swiss Topadur Pharma AG, in collaboration with South Korean Juvic Inc. and the research group led by Prof. Hyungil Jung at Yonsei University in Seoul, has launched a project to improve disease management in systemic...

News 18.12.2023 Zurich-Schlieren, Switzerland, December 18, 2023. Proteomedix AG, a spin-out of ETH Zurich is a Swiss diagnostics company committed to advance prostate cancer care, today announced it has been acquired by US-based, NASDAQ-listed Blue Water Biotech Inc. (NASDAQ: BWV) in a share exchange transaction. The merged entity with the new name...

News 16.12.2023 Zürich, Switzerland, December 14, 2023 InSphero, the global leader in 3D in vitro technology for drug safety and efficacy testing, is proud to announce the appointment of Paul Clémençon, MBA as the new Chief Business Officer (CBO), further strengthening its Executive team. Since joining the company in 2022 as the Head of Business Development, Paul has...

News 11.12.2023 Saint-Prex and Schlieren, Switzerland– 11 December, 2023 – Ferring Pharmaceuticals and Zürich-based microbiome translation company PharmaBiome are today announcing a research & development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology. The deal provides Ferring with exclusive rights to develop, manufacture and commercialize next generation microbiome-based therapeutics within...